BioCentury
ARTICLE | Clinical News

Emixustat: Phase IIb/III data

May 30, 2016 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase IIb/III S.E.A.T.T.L.E. trial in 508 patients with GA secondary to dry age-related AMD showed that once-daily 2.5, 5 and 10 mg oral emixustat each missed...